Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis

Table 1 Demographic, clinical, biochemical and histological characteristics of 184 patients with nonalcoholic steatohepatitis

Variable	NAFLD (n = 184)
Age (yr)	44.6 ± 14.5
Male gender	127 (69.0%)
Body mass index, median (range, kg/m2)	29.3 (19.8-44.5)
Body mass index ≥ 25 kg/m2	156 (84.8%)
Diabetes	69 (37.5%)
Hypertension	54 (29.3%)
Hyperlipidemia	75 (40.8%)
Fasting glucose (mg/dL)	117.9 ± 32.9
HDL cholesterol (md/dL)	47.1 ± 11.8
Triglycerides (mg/dL)	193.8 ± 127.5
LDL cholesterol (mg/dL)	131.7 ± 31.3
Alanine aminotransferase (U/L)	92.4 ± 68.1
Aspartate aminotransferase (U/L)	67.3 ± 39.2
Gamma glutamyltransferase (U/L)	74.1 ± 86.7
Platelet (× 1000/mm3)	244.8 ± 58.6
Albumin (g/dL)	4.5 ± 0.3
Liver stiffness (kPa)	10.9 ± 4.9
Stiffness IQR (kPa)	1.8 ± 3.3
CAP (dB/m)	320.9 ± 37.1
Lower tertile	223-310
Middle tertile	311-339
Higher tertile	340-400
CAP IQR (dB/m)	24.7 ± 9.5
Histology at biopsy
Steatosis grade
1 (5%-33%)	44 (23.9%)
2 (34%-66%)	81 (44.0%)
3 (> 66%)	59 (32.1%)
Stage of fibrosis (Kleiner)
0	20 (10.9%)
1	84 (45.7%)
2	53 (28.8%)
3	21 (11.4%)
4	6 (3.3%)

Data are expressed as the mean ± standard deviation, median (range) or number (%). HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CAP: Controlled attenuation parameter; IQR: Interquartile range; NAFLD: Nonalcoholic fatty liver disease.